7-(Pyrrolidin-1-ylmethyl)quinolin-8-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-(Pyrrolidin-1-ylmethyl)quinolin-8-ol
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.29
• InChiKey: XEUNNZKWRRZAIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel Quinoline-Hepcidine Antagonists
  申请人：Dürrenberger Franz

  公开号：US20120196853A1

  公开（公告）日：2012-08-02

  The present invention relates to novel hepcidin antagonists of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

  本发明涉及一种新型的肝铁蛋白拮抗剂，其一般式为(I)，包括它们的药物组合物以及将其用作药物的用途，特别是用于治疗铁代谢紊乱的疾病，如特别是铁缺乏病和贫血，特别是与慢性炎症性疾病相关的贫血（ACD：慢性疾病贫血和AI：炎症性贫血）。
• [EN] MDRI-INVERSE AGENTS<br/>[FR] AGENTS S'OPPOSANT AU GÈNE MDR1
  申请人：US HEALTH

  公开号：WO2010138686A1

  公开（公告）日：2010-12-02

  A method for inhibiting the growth of drug resistant cells in a subject, comprising identifying a subject having drug resistant cells; and administering to the subject a compound or a pharmaceutically acceptable salt or ester thereof, that is a MDR1 -inverse agent. Also disclosed is a method of inhibiting cancer in a subject, comprising administering to the subject an antiproliferative agent, wherein the antiproliferative effect of the agent is potentiated by P-glycoprotein and the agent is a compound, or a pharmaceutically acceptable salt or ester thereof, that is a MDR1 -inverse agent.
• [EN] 5-NITRO-8-HYDROXYQUINOLINES AS INHIBITORS OF CATHEPSIN B<br/>[FR] 5-NITRO-8-HYDROXYQUINOLÉINES EN TANT QU'INHIBITEURS DE LA CATHEPSINE B
  申请人：UNIV LJUBLJANA

  公开号：WO2011091973A1

  公开（公告）日：2011-08-04

  This invention relates to the compounds or a pharmaceutical acceptable salts, hydrates or solvates thereof, which are inhibitors of cysteine proteases, in particular of cathepsin B. Compounds of the invention are useful in the treatment of diseases in which cathepsin B is implicated.